Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional
Agency: Food and Drug Administration
- 93.103 -- Food and Drug Administration Research
Forecasted opportunityLast Updated: May 13, 2026
Important dates
- Forecasted post date: Not specified
- Forecasted application due date: Not specified
- Forecasted award date: Not specified
- Forecasted project start date: Not specified
- Fiscal Year: 2024
Award details
- Expected project funding: Not specified
- Expected awards: 2
Award min.
$250,000
Award max.
$500,000
- Funding opportunity number:FOR-FD-24-005
- Cost sharing or matching requirement:No
- Funding instrument type:
- Cooperative agreement
- Opportunity Category:Discretionary
- Opportunity Category Explanation:Not specified
- Category of Funding Activity:
- Consumer protection
- Agriculture
- Food and nutrition
- Category Explanation:Not specified
History
- Forecast posted date: November 24, 2023
- Archive date: Not specified
- Version: 2
Summary
The purpose of this funding opportunity is to examine the utility of an in vitro simulated gastrointestinal (GI) dissolution model for the assessment of in vitro performance of amorphous solid dispersion (ASD) drug products under different clinically relevant conditions. The goal is to develop and validate the in vitro mechanistic methodology to provide an improved understanding of impact of food and acid reducing agents on the absorption for test and reference listed drug (RLD) drug products, taking into consideration their potentially different formulations and manufacturing. The bio predictive in vitro mechanistic methodology is intended to correlate the in vitro observations to in vivo outcomes, help define types of in vivo bioequivalence (BE) studies needed for ASD drug products, and inform regulatory decision-making related to mitigating the risk of potential failure modes for therapeutic equivalence for high-risk generic oral drug products.
Eligibility
Nonprofit
- Other Native American tribal organizations
- Nonprofits non-higher education without 501(c)(3)
- Nonprofits non-higher education with 501(c)(3)
Education
- Public and state institutions of higher education
- Private institutions of higher education
- Independent school districts
Business
- For-profit organizations other than small businesses
- Small businesses
Government
- Federally recognized Native American tribal governments
- State governments
- Special district governments
- County governments
- City or township governments
- Public and Indian housing authorities
Miscellaneous
- Unrestricted
- Other
Additional information on eligibility
Documents
No documents are currently available.
Agency contact information
Email: terrin.brown@fda.hhs.gov
terrin.brown@fda.hhs.gov
Link to additional information
No additional information is available
